Le Lézard
Classified in: Health
Subject: FDA

Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec®)

BOCA RATON, Fla., March 4, 2019 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Imatinib Mesylate Tablets, generic for Gleevec® Tablets by Novartis.  Breckenridge's Imatinib Mesylate Tablets product was developed in collaboration with Stason Pharmaceuticals Inc. and will be commercially manufactured by Stason in 100mg and 400mg product strengths. Breckenridge plans to launch the product in the near future.

The product generated annual sales of approximately $654.8 million over the year ending December 31, 2018, according to industry sales data.

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms, including: tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products.

About Stason:
With strong business ties to pharmaceutical interests in China, Japan, and Taiwan, Stason Pharmaceuticals, Inc., established in 1994 and based in Irvine, CA, is a privately held pharmaceutical company involved in drug development, manufacturing, importation and exportation, licensing and acquisition of both generic and branded products. The company's primary area of development is in the area of oncology, and supportive products for the treatment of side effects related to cancer therapy. Additional therapeutic areas include cardiovascular, central nervous system, autoimmune and endocrine disorders.

Gleevec® is a registered trademark of Novartis.

SOURCE Breckenridge Pharmaceutical, Inc.

These press releases may also interest you

at 19:00
StudyKIK, a patient recruitment and technology company that builds digital patient communities and enrollment technology solutions for clinical trials, has launched an e-consent solution with seamless integration to its research site and central...

at 19:00
Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today...

at 18:35
Healthcare Trust, Inc. ("HTI" or the "Company") today announced the pricing of an underwritten public offering of 1,400,000 shares of its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the "Series A Preferred Stock") at a public...

at 18:20
The Canadian Medical Association (CMA) is pleased to see today's Speech from the Throne reflect the need to increase our support for health care in Canada. Specifically, the CMA is encouraged by the government's emphasis in today's address to...

at 18:05
Resverlogix Corp. ("Resverlogix" or the "Company") reminds stakeholders that the Company will hold a conference call and webcast on December 6th at 8:30 am ET to supplement the presentation of prespecified BETonMACE cognition results to be disclosed...

at 18:00
Medicure Inc. ("Medicure" or the "Company") , a cardiovascular pharmaceutical company, today announced that it has reached a settlement agreement with the purchaser of Medicure's interests in Apicore with respect to the amounts heldback under the...

News published on 4 march 2019 at 13:30 and distributed by: